AI Article Synopsis
- Mannitol and furosemide, known for managing intracranial pressure, were hypothesized to also help with refractory lymphedema due to mannitol's ability to draw water out of tissues.
- A 90-year-old woman treated for intracranial hemorrhage showed significant improvement in her long-standing left leg lymphedema after receiving this combination therapy.
- The case suggests that this drug combination may be a viable alternative treatment for refractory lymphedema when standard therapies fail.
Article Abstract
Background: Mannitol is a hyperosmolar agent and the combination of mannitol and furosemide is a widely used treatment for intracranial pressure control. Considering the hypertonic properties of mannitol to move water out of intracellular spaces, we hypothesized that mannitol combined with furosemide could relieve focal tissue swelling in refractory lymphedema.
Case Summary: A 90-year-old female had been diagnosed with intracranial hemorrhage and received a combination of mannitol and furosemide for intracranial pressure control. Independent of the intracranial hemorrhage, she had refractory lymphedema of the left lower extremity since 1998. Remarkably, after receiving the mannitol and furosemide, the patient's lower extremity lymphedema improved dramatically. After the mannitol and furosemide were discontinued, the lymphedema worsened in spite of complete decongestive therapy (CDT) and intermittent pneumatic compression treatment (IPC). To identify the presumed effect of mannitol and furosemide on the lymphedema, these agents were resumed, and the lymphedema improved again.
Conclusion: The present case raises the possibility that a combination of mannitol and furosemide might be considered another effective therapeutic option for refractory lymphedema when CDT and IPC are ineffective.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546829 | PMC |
| http://dx.doi.org/10.12998/wjcc.v9.i29.8804 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Malignant hypertension in a patient with Turner syndrome: A case report.
Medicine (Baltimore)
August 2024
Department of Cardiology, The First College of Clinical Medical Science, China Three Gorges University and Yichang Central People's Hospital, Yichang, China.
Rationale: Turner syndrome is characterized by complete or partial loss of the second sex chromosome. In patients with Turner syndrome, hypertension is well described. However, the literature regarding malignant hypertension is scarce.
View Article and Find Full Text PDFPerioperative optic nerve sheath diameter variations in patients with end-stage renal failure undergoing robotic-assisted kidney transplant: a prospective observational study.
Clin Transplant Res
June 2024
Department of Anesthesia and Critical Care, Aster Medcity, Kochi, India.
Background: Patients with chronic kidney disease (CKD) who undergo hemodialysis are predisposed to interstitial cerebral edema. Robotic-assisted laparoscopic surgery can increase optic nerve sheath diameter (ONSD) and intracranial pressure. The impact of robotic-assisted kidney transplant (RAKT) on ONSD is complicated by the presence of CKD, the administration of furosemide and mannitol, and the manipulation of hemodynamics.
View Article and Find Full Text PDFComparison of preventive effects of combined furosemide and mannitol versus single diuretics, furosemide or mannitol, on cisplatin-induced nephrotoxicity.
Sci Rep
May 2024
Department of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1, Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan.
Article Synopsis
- Cisplatin (CDDP) often causes kidney damage (nephrotoxicity), and diuretics are used to try to prevent this effect, but their effectiveness is unclear.
- This study analyzed data from 396 patients receiving CDDP-based chemotherapy to see if a combination of two diuretics, furosemide and mannitol, was better than using one alone in preventing kidney damage.
- Results showed no significant difference in nephrotoxicity rates between the two groups, and factors like high CDDP dose, hypertension, and lack of magnesium supplementation were more critical risks, emphasizing the need for careful monitoring of these patients.
Prospective assessment of the impact of intraoperative diuretics in kidney transplant recipient surgery.
Can J Surg
April 2024
From the Departments of Surgery (Levine, Rasmussen, Luke, Sener) and Microbiology & Immunology (Sener), Schulich School of Medicine & Dentistry, Western University, London, Ont.; the Matthew Mailing Centre for Translational Transplant Studies, London, Ont. (Lee, Rim, Farokhi, Luke, Sener); the Multi-Organ Transplant Program, London Health Sciences Centre, University Hospital, London, Ont. (Levine, Rasmussen, Luke, Sener); and the Division of Urology, Department of Surgery, University of Alberta, Edmonton, Alta. (Levine, Rasmussen)
Background: The use of intraoperative diuretics, such as furosemide or mannitol, during kidney transplantation has been suggested to reduce the rate of delayed graft function (DGF). The evidence base for this is sparse, however, and there is substantial variation in practice. We sought to evaluate whether the use of intraoperative diuretics during kidney transplantation translated into a reduction in DGF.
View Article and Find Full Text PDFDesign of an Oral Tablet Containing Furosemide Nanoparticles with Elevated Bioavailability.
J Oleo Sci
April 2024
Faculty of Pharmacy, Kindai University.
The solubility and permeability of the Biopharmaceutics Classification System (BCS) class IV drugs, such as furosemide (FUR), are low. Thus, the oral bioavailability of these drugs needs to be augmented. Here, we aimed to design orally disintegrating tablets containing FUR nanoparticles to improve bioavailability after oral administration.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!